ANTI-SCARRING GENE THERAPY
A NOVEL GENE THERAPY VECTOR
​
- Based on a triple mutant AAV6.2FF capsid
- Lower immunogenicity
- Improved transgene expression
-
Cellexa [adeno-associated virus (AAV6) human ensereptide-Fc fusion protein gene therapy]
-
The ensereptide in Cellexa is the human lactoferrin derived peptide linked to human Fc protein. This is Cellastra's Anti-Scaring Fusion protein.
-
The ensereptide has been shown to have higher anti-inflammatory, anti-scarring and anti-bacterial properties, than its full molecule i.e., lactoferrin
-
Scarlexa and Fibrexa are different formulations of Cellexa, where Scarlexa is a dermal formulation and Fibrexa is inhaled formulation.
Propriety Gene Vectors
Mechanism of Action
Expression of Gene Vector in Mice
Product Candidates
Fibrexa for mitigation of respiratory infections
FIBREXA is a formulation for inhalation by high risk patients e.g. elderly or other patients with risk factors for developing long-term complications with fibrosis after respiratory infections (eg. Influenza, RSV and COVID-19).
Figure showing normal lung vs. idiopathic (unknown cause) pulmonary fibrosis.
Scarlexa to prevent dermal scarring after burn injuries
Gene therapy for dermal application to prevent scarring after burn injury. Applied topically by spray or ointment suitable for larger body surface area.
Scarlexa to prevent scarring or adhesions after surgery
For prevention of scarring or adhesions after surgery, Scarlexa is applied before wound closure or injected subcutaneously into the wound area. Shown below is adhesions of the lung (a). Surgery is often used to remove adhesions (b). Treatment with Scarlexa prevents the return of adhesions.
a
b
How Does It Work?
​Administration of the viral gene vector:
-
May Enable continuous production of anti-scarring peptides in the cells of the wound area for many weeks or months.
-
May Help mitigate hyper-immune response (cytokine storm), excessive fibrin formation, secondary infections and excessive scar/fibrosis formation.
​​The peptide disrupts root causes of scarring
-
Inflammation promotes severe scarring
A: Reduced blocking increases fibrinolysis and scar resolution
B: Blocked fibrinolysis promotes scarring
-
Infections cause inflammation which increases scar formation